FIELD: medicine, pharmaceutics.
SUBSTANCE: it is proposed to use 3,11b-cis-dihydrotetrabenazine (earlier available for treatment of hyperkinesis) or its pharmaceutically acceptable salt for production of medical agent to prevent or treat inflammatory disease and according method of prophylactics (treatment). It is demonstrated that all stereoisomers of 3,11b-cis-dihydrotetrabenazine are linked to sigma-1- and sigma-2-receptors, modulate production of cytokines by human monocytes, in high concentrations suppress proliferation of T-cells (T-cells are regulators of inflammation in case of a wide range of diseases). In particular, isomer D reduced production of IL-2, IL-4, IL-5, IL-10, IL-12, TNF-α.
EFFECT: production of pharmaceutical composition for production of medicinal agent for prophylactics or treatment of inflammatory disease.
13 cl, 6 dwg, 14 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIHYDROTETRABENAZENES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2005 |
|
RU2365590C2 |
| PHARMACEUTICAL COMPOUNDS | 2006 |
|
RU2407743C2 |
| APPLICATION OF 3,11b-CIS-DIHYDROTETRABENAZINE FOR TREATMENT OF HUNTINGTON'S DISORDER SYMPTOMS | 2006 |
|
RU2409365C2 |
| PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2783865C2 |
| PHARMACEUTICAL COMPOUND | 2016 |
|
RU2730842C2 |
| TREATMENT OF HYPERKINETIC MOTOR DISORDERS | 2015 |
|
RU2753740C2 |
| (+)-ALPHA-DIHYDROTETRABENAZINE FOR USE IN TREATMENT OF MOTOR DISORDER | 2018 |
|
RU2771164C2 |
| USE OF (−)-α-DIHYDROTETRABENAZINE OR A COMBINATION THEREOF WITH (+)-α-DIHYDROTETRABENAZINE IN THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDER, AS WELL AS CORRESPONDING METHODS | 2018 |
|
RU2768738C2 |
| USING COMPOUNDS BINDING TO SIGMA RECEPTOR LIGANDS FOR TREATING NEUROPATHIC PAIN PROGRESSION CAUSED BY CHEMOTHERAPY | 2009 |
|
RU2537226C2 |
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF ITS USE | 2020 |
|
RU2747991C1 |
